title: [Clinical Characteristics of Prostate Ductal Adenocarcinoma in Kyoto University Hospital].
abstract: Prostate ductal adenocarcinoma is a rare variant of prostate cancer and considered to be more aggressive than the common acinar type of adenocarcinoma. The appropriate treatment guideline for prostate ductal adenocarcinoma has not been established. The aim of the present study was to examine the clinical characteristics and the effectiveness of treatment for prostate ductal adenocarcinoma. From 2005 to 2012, 41 patients were diagnosed to have prostate ductal adenocarcinoma in Kyoto University Hospital. The mean±SD age was 68.6±7.0 years, and the median (range) initial serum PSA level was 9.3 (3.7-217) ng/ml. Among 17 patients who underwent radical prostatectomy, 10 (58.8%) had pT3 disease and 5 (29.4%) had biochemical recurrence during median follow-up of 22.9 months. Out of 19 patients treated with definitive EBRT with endocrine therapy, 2 patients (10.5%) experienced biochemical recurrence with median follow-up of 37.3 months. Five patients were treated with endocrine therapy alone, and 2 (40.0%) of them died of prostate ductal adenocarcinoma. In conclusion, patients with prostate ductal adenocarcinoma were more likely diagnosed as locally advanced diseases than those with prostate acinar adenocarcinoma. However, for patients without metastasis, either surgery or EBRT with endocrine therapy is effective with good prognosis.
authors.affiliation: The Department of Urology, Kyoto University Graduate School of Medicine.
authors.forename: Kenji
authors.initials: K
authors.lastname: Nakamura
authors.affiliation: The Department of Urology, Kyoto University Graduate School of Medicine.
authors.forename: Naoki
authors.initials: N
authors.lastname: Terada
authors.affiliation: The Department of Urology, Kyoto University Graduate School of Medicine.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kobayashi
authors.affiliation: The Department of Urology, Kyoto University Graduate School of Medicine.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Sugino
authors.affiliation: The Department of Urology, Kyoto University Graduate School of Medicine.
authors.forename: Toshinari
authors.initials: T
authors.lastname: Yamasaki
authors.affiliation: The Department of Urology, Kyoto University Graduate School of Medicine.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Matsui
authors.affiliation: The Department of Urology, Kyoto University Graduate School of Medicine.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Imamura
authors.affiliation: The Department of Urology, Kyoto University Graduate School of Medicine.
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Okubo
authors.affiliation: The Department of Urology, Kyoto University Graduate School of Medicine.
authors.forename: Tomomi
authors.initials: T
authors.lastname: Kamba
authors.affiliation: The Department of Urology, Kyoto University Graduate School of Medicine.
authors.forename: Koji
authors.initials: K
authors.lastname: Yoshimura
authors.affiliation: The Department of Urology, Kyoto University Graduate School of Medicine.
authors.forename: Osamu
authors.initials: O
authors.lastname: Ogawa
mesh_terms: D000368:Aged; D044584:Carcinoma, Ductal / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000628:therapy*; D012189:Retrospective Studies
chemical_list: D017430:Prostate-Specific Antigen